ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections

Stock Information for ContraFect Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ContraFect Corporation

ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million
ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company's Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens
ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.